Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Today we look at how RFK Jr. is cementing his power and how his department’s policies are leading some scientists to leave the U.S.
The need-to-know this morning
- Cytokinetics said Chinese regulators approved Myqorzo (formerly aficamten) for the treatment of a serious heart condition known as obstructive hypertrophic cardiomyopathy. An approval decision from the FDA is expected before the end of the year. Sanofi has rights to sell Myqorzo in China.
- DBV Technologies said its Viaskin peanut patch reduced allergic reactions in children, achieving the primary goal of a Phase 3 clinical trial. The company plans to submit for FDA approval next year.
Some scientists are leaving the U.S. as Trump policies destabilize research prospects
The volatility of federal research funding under the Trump administration has stoked fears of a U.S. brain drain. While it’s too early to know how many scientist have left or will leave the country this year, there are some signs that more researchers are looking abroad.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply